Angiotensin II type 1 receptor autoantibody blockade improves cerebral blood flow autoregulation and hypertension in a preclinical model of preeclampsia. (1st October 2020)

• Record Type: Journal Article
• Authors: Duncan, Jeremy W.; Azubuike, Daniel; Booz, George W.; Fisher, Brandon; Williams, Jan M.; Fan, Fan; Ibrahim, Tarek; LaMarca, Babbette; Cunningham, Mark W.
• Is Part Of: Hypertension in pregnancy. Volume 39:Number 4(2020)
• Page Start: 451
• Page End: 460
• Publication Date: 2020-10-01
• Subjects: Preeclampsia -- hypertension -- CBF autoregulation -- BBB Permeability -- AT1-AA -- placental ischemia; Hypertension in pregnancy -- Periodicals; Pregnancy -- Complications -- Periodicals; 618.3261
• DOI: 10.1080/10641955.2020.1833215
• Languages: English
• ISSNs: 1064-1955

Abstract

ABSTRACT: Introduction: Women with preeclampsia (PE) and reduced uterine perfusion pressure (RUPP) pre-clinical rat model of PE have elevated angiotensin II type 1 receptor agonistic autoantibodies (AT1-AA) and cerebrovascular dysfunction. Methods: Sprague Dawley rats had RUPP surgery with/without AT1-AA inhibitor ('n7AAc'144 μg/day) osmotic minipumps. Mean arterial pressure (MAP), CBF autoregulation, blood brain barrier (BBB) permeability, cerebral edema, oxidative stress, and eNOS were assessed. Results: 'n7AAc' improved MAP, restored CBF autoregulation, prevented cerebral edema, elevated oxidative stress, and increased phosphorylated eNOS protein in RUPP rats. Conclusion: Inhibiting the AT1-AA in placental ischemic rats prevents hypertension, cerebrovascular dysfunction, and improves cerebral metabolic function.